Published Date:2023-05-02 Original Link:https://www.onenessbio.com/en/news_detail217_3.htm No 2 Date of announcement 2023/05/02 Time of announcement 17:53:30 Subject The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023. To which item it meets paragraph 12 Date of events 2023/05/05 Statement Date...Read More

Published Date:2023-05-02 Original Link:https://www.onenessbio.com/en/news_detail216_3.htm No 1 Date of announcement 2023/05/02 Time of announcement 17:44:57 Subject Oneness Biotech Co., Ltd. receives a Singaporean patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2023/05/02 Statement Date of occurrence of the event:2023/05/02 Company...Read More